Good news! | KAL Biotech”Experimental Animal Production License” has been successfully approved!

Hendrerit nunc sociis tortor condimentum purus pellentesque dictum.

Recently, KAL Biotech Inc. (hereinafter referred to as “KAL Biotech”), a wholly-owned subsidiary of KCI Biotech Inc, successfully obtained the “Experimental Animal Production License” officially issued by the Jiangsu Provincial Department of Science and Technology. This marks that the KAL Biotech Experimental Animal Breeding Center has obtained official recognition and will be officially put into use. This is an important strategic upgrade for KCI Biotech, which will further meet the technical service needs of global pharmaceutical companies and research institutions in the field of biological experimentation and evaluation research.

KAL Biotech, established in 2023, is a wholly-owned subsidiary of KCI Biotech Inc. Located in Haimen District, Nantong, Jiangsu, it boasts a modern breeding facility spanning 22,400 square meters. As a high-tech enterprise, KALBiotech specializes in the professional breeding and supply of standardized laboratory beagles. Precisely positioned upstream in the biomedical industry chain, the company is committed to providing key experimental animal resources with clear genetic backgrounds, defined health statuses, and meeting international quality standards for global non-clinical drug research (GLP), medical device evaluation, and basic medical research.

KAL Biotech is equipped with comprehensive ventilation, cooling/heating systems, monitoring systems, water and power supply systems, and maternity bed conservation equipment, providing a stable, clean, and comfortable living environment for the growth and breeding of experimental beagles.

Looking ahead to the future

In the future, as the production and breeding base for KCI Biotech experimental beagles, KAL Biotech will continue to strictly adhere to industry standards, continuously enhance its own strength and competitiveness, establish itself as a benchmark for experimental beagles in China, and sincerely provide each customer with high-quality products and services. We aim to become a trusted strategic partner for domestic and international scientific research institutions and pharmaceutical companies, jointly contributing to the advancement of human health.

About KCI Biotech

KCI Biotech and its wholly-owned subsidiary, KMQ Biotech and KAL Biotech are CROs specializing in providing preclinical pharmacodynamics and durability evaluation services for pharmaceutical research and development. The company owns AAALAC-accredited state-of-the-art laboratory animal facilities in Suzhou and Nantong,with a total area of more than 40,000m²,which can meet the needs of various types of preclinical research. The company has a full range of laboratory animal platforms including rats, mice, hamsters, guinea pigs, rabbits, cats, ferrets, dogs, pigs, sheeps and non-human primates. The in vivo pharmacolofical department supplies more than 400 animal disease models for human medicine development research. The BSL2/ABSL2 department supplies more than 100 pathogenic microorganisms, including bacteria, viruses, and fungi for human medicine development research, veterinary medicine and pet medicine. The company also supplies pathology, toxicology, pharmacokinetics, cellular and molecular biology, and medical imaging services. The company has already cooperated with more than 1,000 famous domestic and international pharmaceutical companies , and completed more than 2000 domestic and international projects. With a professional R&D team, rich experience in in vivo pharmacology and pharmacodynamics evaluation, and a professional spirit of integrity and excellence, KCI/KMQ/KAL will provide a full range of preclinical drug discovery and development services for global pharmaceutical companies and research institutions, and establish a professional and efficient drug discovery and evaluation system. KCI Biotech and its wholly-owned subsidiary, KMQ Biotech and KAL Biotech are CROs specializing in providing preclinical pharmacodynamics and durability evaluation services for pharmaceutical research and development. The company owns AAALAC-accredited state-of-the-art laboratory animal facilities in Suzhou and Nantong,with a total area of more than 40,000m²,which can meet the needs of various types of preclinical research. The company has a full range of laboratory animal platforms including rats, mice, hamsters, guinea pigs, rabbits, cats, ferrets, dogs, pigs, sheeps and non-human primates. The in vivo pharmacolofical department supplies more than 400 animal disease models for human medicine development research. The BSL2/ABSL2 department supplies more than 100 pathogenic microorganisms, including bacteria, viruses, and fungi for human medicine development research, veterinary medicine and pet medicine. The company also supplies pathology, toxicology, pharmacokinetics, cellular and molecular biology, and medical imaging services. The company has already cooperated with more than 1,000 famous domestic and international pharmaceutical companies , and completed more than 2000 domestic and international projects . With a professional R&D team, rich experience in in vivo pharmacology and pharmacodynamics evaluation, and a professional spirit of integrity and excellence, KCI/KMQ/KAL will provide a full range of preclinical drug discovery and development services for global pharmaceutical companies and research institutions, and establish a professional and efficient drug discovery and evaluation system.

Your email address will not be published. Required fields are marked *

Good news! | KAL Biotech”Experimental Animal Production License” has been successfully approved!

Leave a Reply

Company

Products

Get in touch

Contact Us